UroGen Pharma (URGN) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
UroGen Pharma (URGN) PT Lowered to $36 at Raymond James
March 11, 2025 9:47 AM EDTRaymond James analyst Reni Benjamin lowered the price target on UroGen Pharma (NASDAQ: URGN) to $36.00 (from $40.00) while maintaining a Outperform rating.
The analyst comments "4Q Jelmyto sales of $24.6M were a bit below $25.6M consensus estimate. We should soon... More
